{"filing":{"accession_number":"0001326110-26-000071","cik":"0001326110","ticker":"IBRX","company_name":"ImmunityBio, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-29","primary_document":"ibrx-20260729.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/ibrx-20260729.htm"},"events":[{"id":22305,"run_id":20165,"accession_number":"0001326110-26-000071","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"ImmunityBio announced that the Emirates Drug Establishment (EDE) of the UAE granted marketing authorization for ANKTIVA across two indications (BCG-unresponsive NMIBC and metastatic NSCLC), expanding its global regulatory footprint to 34 countries. This is a significant regulatory milestone and product approval event that would materially affect investor assessment of the company's commercial prospects and pipeline progress, but it does not fit neatly into the specific financial, governance, or legal categories—it is a strategic operational/commercial achievement in product development and regulatory approval.","company_name":"ImmunityBio, Inc.","ticker":"IBRX","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22212,"accession_number":"0001326110-26-000071","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ImmunityBio announced that the Emirates Drug Establishment (EDE) of the UAE granted marketing authorization for ANKTIVA across two indications (BCG-unresponsive NMIBC and metastatic NSCLC), expanding its global regulatory footprint to 34 countries. This is a significant regulatory milestone and product approval event that would materially affect investor assessment of the company's commercial prospects and pipeline progress, but it does not fit neatly into the specific financial, governance, or legal categories—it is a strategic operational/commercial achievement in product development and regulatory approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:31:41.341963+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22212,"accession_number":"0001326110-26-000071","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ImmunityBio announced that the Emirates Drug Establishment (EDE) of the UAE granted marketing authorization for ANKTIVA across two indications (BCG-unresponsive NMIBC and metastatic NSCLC), expanding its global regulatory footprint to 34 countries. This is a significant regulatory milestone and product approval event that would materially affect investor assessment of the company's commercial prospects and pipeline progress, but it does not fit neatly into the specific financial, governance, or legal categories—it is a strategic operational/commercial achievement in product development and regulatory approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:31:41.341963+00:00","company_name":"ImmunityBio, Inc.","ticker":"IBRX","filing_date":"2026-07-30"}]}